Mucormycosis in patients with COVID‐19: A cross‐sectional descriptive multicentre study from Iran
Top Cited Papers
Open Access
Abstract
Purpose: The aim of the study was to report clinical features, contributing factors and outcome of patients with coronavirus disease 2019 (COVID‐19)‐associated mucormycosis (CAM).Methods: A cross‐sectional descriptive multicentre study was conducted on patients with biopsy‐proven mucormycosis with RT‐PCR‐confirmed COVID‐19 from April to September 2020. Demographics, the time interval between COVID‐19 and mucormycosis, underlying systemic diseases, clinical features, course of disease and outcomes were collected and analysed.Results: Fifteen patients with COVID‐19 and rhino‐orbital mucormycosis were observed. The median age of patients was 52 years (range 14–71), and 66% were male. The median interval time between COVID‐19 disease and diagnosis of mucormycosis was seven (range: 1–37) days. Among all, 13 patients (86%) had diabetes mellitus, while 7 (46.6%) previously received intravenous corticosteroid therapy. Five patients (33%) underwent orbital exenteration, while seven (47%) patients died from mucormycosis. Six patients (40%) received combined antifungal therapy and none that received combined antifungal therapy died.Conclusion: Clinicians should be aware that mucormycosis may be complication of COVID‐19 in high‐risk patients. Poor control of diabetes mellitus is an important predisposing factor for CAM. Systematic surveillance for control of diabetes mellitus and educating physician about the early diagnosis of CAM are suggested.Keywords
Funding Information
- Tehran University of Medical Sciences and Health Services (99‐1‐252‐47469)
This publication has 32 references indexed in Scilit:
- Clinical Characteristics of Coronavirus Disease 2019 in ChinaNew England Journal of Medicine, 2020
- Overlapping and discrete aspects of the pathology and pathogenesis of the emerging human pathogenic coronaviruses SARS‐CoV, MERS‐CoV, and 2019‐nCoVJournal of Medical Virology, 2020
- COVID-19 Infection Presenting with CT Halo SignRadiology: Cardiothoracic Imaging, 2020
- Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research ConsortiumThe Lancet Infectious Diseases, 2019
- Invasive pulmonary aspergillosis complicating severe influenza: epidemiology, diagnosis and treatmentCurrent Opinion in Infectious Diseases, 2018
- MucormycosisCurrent Opinion in Hematology, 2014
- Diagnosis and treatment of mucormycosis in patients with hematological malignancies: guidelines from the 3rd European Conference on Infections in Leukemia (ECIL 3)Haematologica, 2012
- The ecology of the Zygomycetes and its impact on environmental exposureClinical Microbiology and Infection, 2009
- Epidemiology and Outcome of Zygomycosis: A Review of 929 Reported CasesClinical Infectious Diseases, 2005
- Novel Perspectives on Mucormycosis: Pathophysiology, Presentation, and ManagementClinical Microbiology Reviews, 2005